Related Experiment Video
Updated: Jun 29, 2026
12:43
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
[Dendritic cell sarcoma: 4 cases report with literature review]
Jian Li1, Ming-Hui Duan, Bing Han
1Department of Hematology, Peking Union Medical College Hospital, CAMS and PUMC, Beijing 100730, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|October 11, 2008
Summary
Dendritic cell sarcomas (DCS) are rare, with distinct clinical features and prognoses. Follicular, interdigitating, and Langerhans cell types show varied outcomes, with most patients experiencing a poor prognosis.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Dendritic cell sarcoma (DCS) encompasses rare malignancies.
- Understanding the distinct subtypes, including follicular dendritic cell sarcoma (FDCS), interdigitating dendritic cell sarcoma (IDCS), and Langerhans cell sarcoma (LCS), is crucial for diagnosis and treatment.
Observation:
- Case studies presented variations in clinical presentation, such as fever and lymphadenopathy in FDCS and paraneoplastic pemphigus in IDCS.
- Immunohistochemistry revealed specific markers: CD21/CD35 for FDCS, S-100 for IDCS, and CD1a/S-100 with Birbeck granules for LCS.
- Chemotherapy regimens like CHOP showed limited efficacy, with disease progression observed in some cases.
Findings:
- Dendritic cell sarcoma subtypes exhibit unique clinical and pathological characteristics.
- Treatment responses varied, with some patients achieving remission while others experienced disease progression or relapse.
- The overall prognosis for most patients with dendritic cell sarcoma is poor.
Implications:
- Further research into targeted therapies for dendritic cell sarcoma subtypes is warranted.
- Early and accurate diagnosis through immunohistochemistry is critical for patient management.
- Improved understanding of DCS biology may lead to better therapeutic strategies and improved patient outcomes.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...